ACLX Relative Valuation - Arcellx Inc - Alpha Spread
A

Arcellx Inc
NASDAQ:ACLX

Watchlist Manager
Arcellx Inc
NASDAQ:ACLX
Watchlist
Price: 86.61 USD 1.38% Market Closed
Market Cap: 4.6B USD
Have any thoughts about
Arcellx Inc?
Write Note

Relative Value

The Relative Value of one ACLX stock under the Base Case scenario is 38.83 USD. Compared to the current market price of 86.61 USD, Arcellx Inc is Overvalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACLX Relative Value
Base Case
38.83 USD
Overvaluation 55%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
29
Median 3Y
21.1
Median 5Y
21.1
Industry
7.8
Forward
33.3
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-9.9
Industry
23.7
Forward
-53.3
vs History
vs Industry
11
Median 3Y
-8.8
Median 5Y
-8.8
Industry
22.3
vs History
vs Industry
8
Median 3Y
-7.6
Median 5Y
-7.6
Industry
24.8
vs History
3
vs Industry
13
Median 3Y
5.9
Median 5Y
5.9
Industry
2.5
vs History
21
vs Industry
27
Median 3Y
16.8
Median 5Y
16.8
Industry
7.6
Forward
29.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
vs History
vs Industry
Median 3Y
-7
Median 5Y
-7
Industry
4.8
Forward
-60.6
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
4.5
Forward
-37.5
vs History
vs Industry
12
Median 3Y
-5.7
Median 5Y
-5.7
Industry
6.4
vs History
vs Industry
9
Median 3Y
-5.4
Median 5Y
-5.4
Industry
4.4
vs History
18
vs Industry
18
Median 3Y
11.4
Median 5Y
11.4
Industry
4.8

Multiples Across Competitors

ACLX Competitors Multiples
Arcellx Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arcellx Inc
NASDAQ:ACLX
4.6B USD 32.1 -86.2 -53.3 -51.2
US
Abbvie Inc
NYSE:ABBV
341.7B USD 6.2 64.5 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
181.2B USD 5.9 57.9 20.2 36.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
127.2B USD 9.4 29.4 25.8 28.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120B USD 11.6 -244.9 26 27.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
US
Gilead Sciences Inc
NASDAQ:GILD
104.6B USD 3.8 99.3 9.4 12
AU
CSL Ltd
ASX:CSL
141.9B AUD 6.5 36.6 22.4 27.9
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.1B USD 15 -481 211.7 325.9
P/E Multiple
Earnings Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average P/E: 57.5
Negative Multiple: -86.2
N/A
US
Abbvie Inc
NYSE:ABBV
64.5
406%
US
Amgen Inc
NASDAQ:AMGN
57.9
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.4
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.9
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
AU
CSL Ltd
ASX:CSL
36.6
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -481 N/A
EV/EBITDA Multiple
EBITDA Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average EV/EBITDA: 47.3
Negative Multiple: -53.3
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.8
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
39%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
211.7
N/A
EV/EBIT Multiple
EBIT Growth
US
A
Arcellx Inc
NASDAQ:ACLX
Average EV/EBIT: 68.9
Negative Multiple: -51.2
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.7
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.6
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
38%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
AU
CSL Ltd
ASX:CSL
27.9
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
325.9
N/A

See Also

Discover More
Back to Top